Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides.
Chem Commun (Camb)
; 57(26): 3283-3286, 2021 Apr 04.
Article
in English
| MEDLINE | ID: covidwho-1112012
ABSTRACT
SARS-CoV-2 Spike protein RBD interacts with the hACE2 receptor to initiate cell entry and infection. We set out to develop lactam-based i,i + 4 stapled hACE2 peptides targeting SARS-CoV-2. In vitro screening demonstrates the inhibition of the Spike protein RBD-hACE2 complex formation by the hACE221-55A36K-F40E stapled peptide (IC50 3.6 µM, Kd 2.1 µM), suggesting that hACE2 peptidomimetics could form the basis for the development of anti-COVID-19 therapeutics.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Peptides
/
Spike Glycoprotein, Coronavirus
/
Angiotensin-Converting Enzyme 2
/
SARS-CoV-2
/
COVID-19
Limits:
Humans
Language:
English
Journal:
Chem Commun (Camb)
Journal subject:
Chemistry
Year:
2021
Document Type:
Article
Affiliation country:
D0cc08387a
Similar
MEDLINE
...
LILACS
LIS